Supporting data for thesis “Therapeutic Effects of Ganoderma and Its Active Ingredients on Microglial Activation and Polarization in Multiple Sclerosis Treatment”

Supporting data for thesis “Therapeutic Effects of Ganoderma and Its Active Ingredients on Microglial Activation and Polarization in Multiple Sclerosis Treatment”Multiple Sclerosis (MS), a neurodegenerative disease infecting the central nervous system (CNS), without an effective therapeutic strategy currently. Seeking novel therapeutic strategies for MS is crucial due to its high prevalence and high economic burden. This study investigates the potential of Ganoderma Lucidum Spore Lehuo(GLS) powder, nature product derived from Ganoderma, as a therapeutic agent for MS, with no prior studies examined GLS powder's efficacy in MS treatment. The study used an experimental autoimmune encephalomyelitis (EAE) mouse model to test the hypothesis that GLS could mitigate MS by inhibiting microglial activation and promoting a shift towards an anti-inflammatory M2-like state.The results demonstrated that GLS treatment effectively ameliorated the severity of the disease, and reduced the inflammatory infiltration/demyelination, microglial activation and M2-like polarization in the spinal cord. Meanwhile, GLS could reduce the microglial RNS releasement via suppressing the nuclear factor-κB (NF-κB) signaling pathway in the inflammatory-related BV2 cell model. The in vitro experiments on microglia and neuronal cells also exert protective effects on neurons. Taken together, we conclude that GLS has therapeutic values for treating EAE/MS and decreases the disease severity via attenuating the activation and polarization of microglia to have anti-inflammatory, anti-oxidative effects and inhibiting microglial-derived neuronal death. Further investigation could lead to the development of a promising novel therapeutic agent for Multiple Sclerosis.

支持论文《灵芝及其活性成分对多发性硬化症中微胶质激活和极化的治疗作用》的数据。多发性硬化症（MS）是一种影响中枢神经系统的神经退行性疾病，目前尚无有效的治疗策略。鉴于其高发病率和高经济负担，寻求MS的新型治疗方案至关重要。本研究探究了灵芝（Ganoderma Lucidum）孢子粉（GLS）作为MS治疗药物的潜力，此前尚无研究评估GLS粉在MS治疗中的有效性。研究采用实验性自身免疫性脑脊髓炎（EAE）小鼠模型，以验证GLS通过抑制微胶质激活并促进向抗炎的M2样状态转变，从而减轻MS的假设。结果显示，GLS治疗有效改善了疾病的严重程度，并减少了脊髓中的炎症浸润/脱髓鞘、微胶质激活和M2样极化。同时，GLS可以通过抑制炎症相关的BV2细胞模型中核因子-κB（NF-κB）信号通路来减少微胶质的活性氮（RNS）释放。在体外对微胶质和神经元细胞的实验也显示出对神经元的保护作用。综合来看，我们得出结论，GLS在治疗实验性自身免疫性脑脊髓炎（EAE）/多发性硬化症方面具有治疗价值，通过减轻微胶质的活化和极化，产生抗炎、抗氧化作用，并抑制微胶质来源的神经元死亡，从而降低疾病严重程度。进一步的调查可能有助于开发一种具有广阔前景的新型治疗MS的药物。